Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial-Reference-Cited by-同舟云学术

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

Published:2021-08 Issue:2 Volume:162 Page:375-381
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Aghajanian Carol,Bookman Michael A.,Fleming Gini F.,Swisher Elizabeth M.,Steffensen Karina D.,Friedlander Michael,Okamoto Aikou,Jackson Camille Gunderson,Sullivan Danielle,Ratajczak Christine K.,Coleman Robert L.

Funder

AbbVie

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference11 articles.

1. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer;Coleman;N. Engl. J. Med.,2019

2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur. J. Cancer,2009

3. Update on imaging of ovarian cancer;Forstner;Curr. Radiol. Rep.,2016

4. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis;Amit;Eur. J. Cancer,2011

5. A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials;Dello Russo;Eur. J. Clin. Pharmacol.,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting;The Prostate;2024-04-29

2. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-01

3. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma;Molecular Cancer Therapeutics;2023-09-15

4. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials;World Journal of Surgical Oncology;2023-05-23

5. Reply to R. Sun et al;Journal of Clinical Oncology;2023-04-01